Literature DB >> 20733351

A pathologist's road map to benign, precancerous, and malignant intraepithelial proliferations in the fallopian tube.

Mitra Mehrad1, Gang Ning, Eleanor Y Chen, Karishma K Mehra, Christopher Paul Crum.   

Abstract

The fallopian tube has recently emerged as an important site of origin for not only early serous cancer in women with inherited mutations in BRCA1/BRCA2 but as a source of many pelvic serous carcinomas. With this increased attention has come the inevitable need to sort out what epithelial abnormalities are clinically important and how they should be reported by the practicing pathologist. This review addresses 4 categories of tubal epithelial change: (1) metaplasias; (2) nonmalignant atypias; (3) potential precursors, including secretory cell outgrowths and p53 signatures; and (4) tubal intraepithelial carcinomas. A modified protocol for sectioning the fallopian tube (SEE-FIM) is discussed and each of the above topics is covered in the context of its differential diagnosis and recommendations for reporting are included. Finally, the rationale for close inspection of the tube, both in presumed benign and malignant disease, is discussed, with reference to an ongoing multi-institutional web-based project (Pelvic-ovarian Cancer Interception project).

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20733351     DOI: 10.1097/PAP.0b013e3181ecdee1

Source DB:  PubMed          Journal:  Adv Anat Pathol        ISSN: 1072-4109            Impact factor:   3.875


  25 in total

1.  Fallopian tube as main source for ovarian and pelvic (non-endometrial) serous carcinomas.

Authors:  Wenxin Zheng; Oluwole Fadare
Journal:  Int J Clin Exp Pathol       Date:  2012-03-25

2.  Pathology findings and clinical outcomes after risk reduction salpingo-oophorectomy in BRCA mutation carriers: a multicenter Spanish study.

Authors:  L Minig; S Cabrera; R Oliver; A Couso; M J Rubio; S Iacoponi; M B Martin-Salamanca; S Carballo-Rastrilla; J M Cádenas-Rebollo; A García-Garcia; B Gil-Ibáñez; M J Juan-Fita; M G Patrono
Journal:  Clin Transl Oncol       Date:  2018-04-05       Impact factor: 3.405

3.  Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance.

Authors:  Rachel A Davidowitz; Laura M Selfors; Marcin P Iwanicki; Kevin M Elias; Alison Karst; Huiying Piao; Tan A Ince; Michael G Drage; Judy Dering; Gottfried E Konecny; Ursula Matulonis; Gordon B Mills; Dennis J Slamon; Ronny Drapkin; Joan S Brugge
Journal:  J Clin Invest       Date:  2014-04-24       Impact factor: 14.808

4.  Opportunistic salpingectomy during vaginal hysterectomy for a benign pathological condition.

Authors:  Gery Lamblin; Capucine Meysonnier; Stéphanie Moret; Béatrice Nadaud; Georges Mellier; Gautier Chene
Journal:  Int Urogynecol J       Date:  2017-07-13       Impact factor: 2.894

5.  An Alternate Diagnostic Algorithm for the Diagnosis of Intraepithelial Fallopian Tube Lesions.

Authors:  Marie E Perrone; Nicholas P Reder; Sergay N Agoff; Rochelle L Garcia; Kathy J Agnew; Barbara M Norquist; Kathryn P Pennington; Elizabeth M Swisher; Mark R Kilgore
Journal:  Int J Gynecol Pathol       Date:  2020-05       Impact factor: 2.762

Review 6.  The oviduct and ovarian cancer: causality, clinical implications, and "targeted prevention".

Authors:  Christopher P Crum; Frank D McKeon; Wa Xian
Journal:  Clin Obstet Gynecol       Date:  2012-03       Impact factor: 2.190

Review 7.  [Preneoplasias of ovarian carcinoma: biological and clinical aspects of different pathways of tumorigenesis].

Authors:  A Staebler
Journal:  Pathologe       Date:  2011-11       Impact factor: 1.011

8.  Human ovarian cancer stroma contains luteinized theca cells harboring tumor suppressor gene GT198 mutations.

Authors:  Min Peng; Hao Zhang; Lahcen Jaafar; John I Risinger; Shuang Huang; Nahid F Mivechi; Lan Ko
Journal:  J Biol Chem       Date:  2013-10-04       Impact factor: 5.157

9.  A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development.

Authors:  Cheryl A Sherman-Baust; Elisabetta Kuhn; Blanca L Valle; Ie-Ming Shih; Robert J Kurman; Tian-Li Wang; Tomokazu Amano; Minoru S H Ko; Ichiro Miyoshi; Yoshihiko Araki; Elin Lehrmann; Yongqing Zhang; Kevin G Becker; Patrice J Morin
Journal:  J Pathol       Date:  2014-07       Impact factor: 7.996

10.  Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers.

Authors:  Alison M Karst; Paul M Jones; Natalie Vena; Azra H Ligon; Joyce F Liu; Michelle S Hirsch; Dariush Etemadmoghadam; David D L Bowtell; Ronny Drapkin
Journal:  Cancer Res       Date:  2013-12-23       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.